Irreversible antagonism at the adrenergic alpha-receptor: the role of calcium.
D000316:Adrenergic alpha-Agonists / Q000037:antagonists & inhibitors; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology; D002127:Calcium Isotopes; D003981:Diazoxide / Q000494:pharmacology; D003983:Dibenzylchlorethamine / Q000494:pharmacology; D003992:Dibucaine / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009281:Naphthalenes / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology*; D013748:Tetracaine / Q000494:pharmacology; D014649:Vas Deferens / Q000187:drug effects / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D002127:Calcium Isotopes; D009281:Naphthalenes; D010627:Phenethylamines; D013565:Sympatholytics; D013748:Tetracaine; D010643:Phenoxybenzamine; D003983:Dibenzylchlorethamine; D003992:Dibucaine; D003981:Diazoxide; D002118:Calcium; D009638:Norepinephrine; D007213:Indomethacin